# An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1

> **NCT03350451** · PHASE2 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- PH1
- Primary Hyperoxaluria
- RNAi Therapeutic
- siRNA
- AGT

## Interventions

- **DRUG:** Lumasiran

## Key facts

- **NCT ID:** NCT03350451
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-04
- **Primary completion:** 2023-02-07
- **Final completion:** 2023-02-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03350451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03350451, "An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03350451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*